(2) if he will estimate the number of patients with rheumatoid arthritis who will not be provided with sequential treatments with anti-TNF drugs over the next five years as a result of the ruling by the National Institute for Health and Clinical Excellence on the issue;
(3) what records he holds for benchmarking purposes on the use of anti-TNF treatments in other EU countries; what assessment he has made of how that pattern of use differs from (a) that of its use in England and (b) the differential results of that use in the UK and other member states; and if he will make a statement.
We have made no estimate of the proportion of patients with rheumatoid arthritis who are expected to receive a second anti-TNF treatment.
We have made no estimate of the number of patients with rheumatoid arthritis who are expected not be provided with sequential treatments with anti-TNF drugs over the next five years. The Department holds no records on the use of anti-TNF treatments in other EU countries.